Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Apatinib with SOX as Neoadjuvant Therapy for Advanced Gastric Cancer
NCT05699655Phase 3Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in gastric cancer (GC), sponsored by Fujian Medical University Cancer Hospital. Started May 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05699655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699655.